The Diagnostic Pathway and Your Biopsy
At a Glance
A breast adenoma diagnosis combines imaging with a core needle biopsy and a check that the tissue result matches the scan. A benign, matching result often leads to monitoring, while a mismatch or concerning feature may require another biopsy or surgical removal.
The journey from finding a breast lump to receiving a final diagnosis involves several distinct steps designed to ensure accuracy. Because a breast adenoma can look very similar to other types of breast lumps—including both common fibroadenomas and, more rarely, certain types of cancer—your medical team uses a combination of imaging and tissue sampling to reach a definitive conclusion.
Step 1: Specialized Imaging
The first step in evaluating a breast lump is usually imaging. The type of test you receive typically depends on your age and the specific characteristics of the lump.
- Ultrasound: This is often the first-line tool for patients under 30 and those who are currently pregnant or breastfeeding [1][2]. On an ultrasound, a tubular adenoma often appears as a smooth, oval, dark (hypoechoic) mass [3].
- Diagnostic Mammography: For patients age 30 and older, a mammogram is often added to the assessment (and can still be used during pregnancy or lactation if clinically indicated) [4]. It allows doctors to look for specific patterns, such as calcifications (tiny calcium deposits) or architectural distortion (areas where the breast tissue looks pulled or abnormal) [5][6].
The BI-RADS Score
Radiologists use a standardized system called BI-RADS to communicate how concerned they are about an imaging finding [7].
- BI-RADS 3: Means “probably benign.” There is less than a 2% chance of cancer, and the standard recommendation is usually short-interval follow-up imaging [8][9].
- BI-RADS 4: Means “suspicious.” This category is broad (ranging from a 2% to 95% chance of malignancy) and usually requires a biopsy to confirm the diagnosis [10][11].
Step 2: The Core Needle Biopsy
While imaging provides a “picture” of the lump, a core needle biopsy (CNB) looks at the actual cells to help establish the diagnosis [1]. Unlike a fine needle aspiration (FNA)—which only pulls out individual cells—a core biopsy removes small “cores” or cylinders of tissue [12]. This allows the pathologist to see the architecture of the tissue (how the cells are arranged), which is vital for distinguishing an adenoma from a more complex growth [13][14].
However, a core biopsy is not magic. It relies on the needle hitting the right spot. A core sample can occasionally miss a heterogeneous area, which is why the overall clinical picture matters.
Step 3: Radiologic-Pathologic Concordance
The most critical part of your diagnosis is a step called radiologic-pathologic concordance. This is a safety check where your care team asks: “Does the pathology adequately explain the imaging finding, and was the sample representative?” [15].
- Concordant: If a lump looked like a simple, benign mass on an ultrasound and the biopsy comes back as a “tubular adenoma,” the findings reasonably explain one another. You can usually move to routine monitoring [16].
- Discordant: If the imaging looked highly suspicious (BI-RADS 4C or 5) but the biopsy only showed “normal breast tissue” or a “benign adenoma,” the results are discordant [17]. Your doctor will likely recommend a repeat biopsy or surgical removal to be sure nothing was missed [16][18].
Understanding Your Pathology Report
Pathology reports use dense medical language. You do not need to diagnose yourself, but reviewing these key concepts with your clinician can be helpful. A typical report for a benign tubular adenoma will assess:
- Subtype and Diagnosis: The specific name of the lesion (e.g., tubular adenoma).
- Atypia: The pathologist looks for abnormal cells. The absence of atypia is highly reassuring [2].
- Myoepithelial Pattern: The pathologist may use special stains to check the cell layers. An intact myoepithelial layer supports a benign diagnosis [19][18].
- Mitotic Activity: Mitoses indicate dividing cells. While high levels are concerning, an occasional mitosis can occur in perfectly benign lesions, especially during lactation. It is evaluated in context with the rest of the tissue.
If your report mentions an “indeterminate fibroepithelial lesion” or “increased stromal cellularity,” your doctor may want to evaluate you further to rule out a phyllodes tumor, a different type of growth that sometimes requires surgical removal [14].
Common questions in this guide
How is a breast adenoma evaluated after a lump is found?
What do BI-RADS 3 and BI-RADS 4 mean?
Why is a core needle biopsy used instead of a fine-needle aspiration?
What does it mean if my biopsy and imaging are concordant?
What pathology findings support a benign tubular adenoma?
Can a benign breast biopsy still need additional evaluation?
What does an indeterminate fibroepithelial lesion mean on a breast biopsy?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on breast adenoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What was the BI-RADS score on my imaging report, and how does it relate to my biopsy results?
- 2.Is the pathology result 'concordant' with what you saw on the ultrasound or mammogram?
- 3.Does my pathology report show any high-risk or atypical features?
- 4.Why was a core needle biopsy chosen over a fine needle aspiration in my case?
- 5.If the biopsy showed a benign adenoma but the lump continues to grow, what are the next steps for evaluation?
References
References (19)
- 1
Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging.
Evans A, Trimboli RM, Athanasiou A, et al.
Insights into imaging 2018; (9(4)):449-461 doi:10.1007/s13244-018-0636-z.
PMID: 30094592 - 2
Breast Lesions during Pregnancy - a Diagnostic Challenge: Case Report.
Beyer I, Mutschler N, Blum KS, Mohrmann S
Breast care (Basel, Switzerland) 2015; (10(3)):207-10 doi:10.1159/000381823.
PMID: 26557826 - 3
Imaging manifestations of ductal adenoma of the breast: A case report.
Zhu Y, Yu H, Zheng Z, et al.
Open life sciences 2024; (19(1)):20220917 doi:10.1515/biol-2022-0917.
PMID: 39022161 - 4
Common Breast Problems.
Salzman B, Collins E, Hersh L
American family physician 2019; (99(8)):505-514.
PMID: 30990294 - 5
[Mammography-Guided Interventional Procedure].
Choi WJ, Kim HH
Journal of the Korean Society of Radiology 2023; (84(2)):320-331 doi:10.3348/jksr.2022.0145.
PMID: 37051394 - 6
Tomosynthesis-detected Architectural Distortion: Management Algorithm with Radiologic-Pathologic Correlation.
Durand MA, Wang S, Hooley RJ, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2016; (36(2)):311-21 doi:10.1148/rg.2016150093.
PMID: 26963448 - 7
An audit of the results of ultrasound-guided core needle biopsy of mammography versus ultrasound screen-detected breast lesions.
Rhee SJ, Han BK, Ko ES, et al.
Journal of clinical ultrasound : JCU 2017; (45(5)):261-266 doi:10.1002/jcu.22454.
PMID: 28182285 - 8
Understanding BI-RADS Category 3.
Fazeli S, Stepenosky J, Guirguis MS, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240169 doi:10.1148/rg.240169.
PMID: 39636752 - 9
Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.
Berg WA, Berg JM, Sickles EA, et al.
Radiology 2020; (296(1)):32-41 doi:10.1148/radiol.2020192641.
PMID: 32427557 - 10
MRI in the Assessment of BI-RADS® 4 lesions.
Leithner D, Wengert G, Helbich T, et al.
Topics in magnetic resonance imaging : TMRI 2017; (26(5)):191-199 doi:10.1097/RMR.0000000000000138.
PMID: 28961568 - 11
[Breast Imaging Reporting and Data System (BI-RADS): Advantages and Limitations].
Choi JS
Journal of the Korean Society of Radiology 2023; (84(1)):3-14 doi:10.3348/jksr.2022.0142.
PMID: 36818717 - 12
Clinical Significance of Fine Needle Aspiration in Managing Patients with Breast Lesions.
Dinas K, Pratilas GC, Nasioutziki M, et al.
Folia medica 2018; (60(3)):364-372.
PMID: 30355841 - 13
Evaluation of Breast Lump - Comparison between True-cut Needle Biopsy and FNAC in MMCH: A Study of 100 Cases.
Kamal MZ, Banu NR, Alam MM, et al.
Mymensingh medical journal : MMJ 2020; (29(1)):48-54.
PMID: 31915335 - 14
Benign phyllodes tumor with tubular adenoma-like epithelial component in FNAC: A diagnostic pitfall.
Panda KM
Journal of cytology 2016; (33(4)):224-226 doi:10.4103/0970-9371.190456.
PMID: 28028339 - 15
Mimickers of breast malignancy: imaging findings, pathologic concordance and clinical management.
Guirguis MS, Adrada B, Santiago L, et al.
Insights into imaging 2021; (12(1)):53 doi:10.1186/s13244-021-00991-x.
PMID: 33877461 - 16
Breast tubular adenoma: diagnostic challenges and management insights from a six-case series.
Ng WR, Pellegrino S, Macindoe C, et al.
Journal of surgical case reports 2026; (2026(9)):rjag865 doi:10.1093/jscr/rjag865.
PMID: 42813196 - 17
Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast Lesions.
Zouzos A, Fredriksson I, Foukakis T, et al.
Biomedicines 2025; (13(12)) doi:10.3390/biomedicines13122897.
PMID: 41462910 - 18
Tubular Adenoma of the Breast: Radiologic-Pathologic Correlation.
Joo GJ, Carter GJ, Berg WA
Journal of breast imaging 2023; (5(6)):703-711 doi:10.1093/jbi/wbad066.
PMID: 38141235 - 19
Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.
Ingyin H, Solomon JP, Li Y, et al.
Histopathology 2026; (88(6)):1229-1235 doi:10.1111/his.70082.
PMID: 41456879
This page is for informational purposes only and does not constitute medical advice. A radiologist, pathologist, or breast specialist should interpret your imaging and biopsy results and advise you about next steps.